NCT00447382View on ClinicalTrials.gov

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin detemir

NN304 injected s.c. (under the skin). Given as basal insulin.

DRUG

insulin aspart

Injected s.c. (under the skin). Given as bolus insulin.

DRUG

insulin detemir

NN729 injected s.c. (under the skin). Given as basal insulin

Trial Locations (5)

1000

Skopje

7925

Cape Town

11000

Belgrade

60590

Frankfurt

119034

Moscow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY